It is proposed to prepare a novel lung-targeted methylprednisolone succinate lipid nanoparticle formulation (NSSLs-MPS-SPANb) by using methylprednisolone succinate sodium (MPS) as the therapeutic drug, long-circulating nanoliposomes (NSSLs) modified with polyethylene glycol 2000-distearoylphosphatidylethanolamine (DSPE-PEG-2000) as the drug carrier, and SP-A nanobodies (SPANb) as a specific targeting agent for lung tissue. The aim is to demonstrate the active targeting of this new dosage form in the lungs through animal experiments. Successfully preparing a novel glucocorticoid formulation with lung targeting will ultimately lead to its clinical application. It is expected to obtain 1-2 international invention patents and develop a new drug with originality in China. The main significance lies in: The first development of a new corticosteroid drug targeting specifically the human lung tissue distribution, providing an efficient and low-toxicity new formulation of corticosteroids for various lung inflammatory diseases, especially severe pneumonia and acute lung injury represented by SARS and avian influenza. This fundamentally solves the problem of systemic non-selective distribution of corticosteroids and has great potential for clinical translation and application. It also explores scientific methods and pathways for developing other tissue-targeted new drugs and establishes a research platform, with great potential for expansion.